 SAN FRANCISCO--BUSINESS WIRE--Akero Therapeutics, Inc. Nasdaq: AKRO, a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis NASH and other serious metabolic disorders, today announced that management will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 10:50 a.m. EST on Tuesday, January 12, 2021. A live webcast of the presentation will be available through the investor relations section of the 